Antibody-dependent cellular cytotoxicity in patients on chronic hemodialysis

American Journal of Nephrology

Volumn 38, Issue 5, 2013, Pages 379-387

  Koch, Till ^a   Derer, Stefanie ^b   Staudinger, Matthias ^b   Rossen, Kai ^a   Glorius, Pia ^b   Peipp, Matthias ^b   Kellner, Christian ^b   Kunzendorf, Ulrich ^a   Valerius, Thomas ^b   Dechant, Michael ^a  

^a Nephrology and Hypertension ^*  (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Antibody dependent cellular cytotoxicity; Dialysis; Human IgG2 antibody; Peripheral blood mononuclear cells; Polymorphonuclear cells

Indexed keywords

CETUXIMAB; FC RECEPTOR IIA; PANITUMUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL ASSAY; CELL FUNCTION; CELL ISOLATION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; EFFECTOR CELL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; ANTIBODY AFFINITY; END STAGE RENAL DISEASE;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-6; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; MONOCYTES; NEUTROPHILS; RECEPTORS, FC; RENAL DIALYSIS; RENAL INSUFFICIENCY;

EID: 84886027554     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000355972     Document Type: Article

References (37)

1. Rahman A, White RM: Cytotoxic anticancer agents and renal impairment study: the challenge remains. J Clin Oncol 2006; 24: 533-536. (Pubitemid 46630412)
2. Weiner LM, Surana R, Wang S: Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10: 317-327.
3. Meibohm B, Zhou H: Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol 2012; 52: 54S-62S
4. Peipp M, Dechant M, Valerius T: Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr Opin Immunol 2008; 20: 436-443.
5. van de Winkel JG, Anderson CL: Biology of human immunoglobulin G Fc receptors. J Leukoc Biol 1991; 49: 511-524.
6. Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443-446. (Pubitemid 30208162)
7. Carter PJ: Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6: 343-357.
8. Ravetch JV, Bolland S: IgG Fc receptors. Annu Rev Immunol 2001; 19: 275-290. (Pubitemid 32368037)
9. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, Derer S, Beyer T, Lohse S, Bleeker WK, Peipp M, Parren PW, van de Winkel JG, Valerius T, Dechant M: Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010; 184: 512-520.
10. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF: The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199: 1659-1669. (Pubitemid 38821999)
11. Biburger M, Aschermann S, Schwab I, Lux A, Albert H, Danzer H, Woigk M, Dudziak D, Nimmerjahn F: Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 2011; 35: 932-944.
12. Peipp M, Dechant M, Valerius T: Sensitivity and resistance to EGF-R inhibitors: Approaches to enhance the efficacy of EGF-R antibodies. MAbs 2009; 1: 590-599.
13. Miyamoto T, Carrero JJ, Stenvinkel P: Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 2011; 20: 662-668.
14. Carracedo J, Ramirez R, Soriano S, Alvarez de Lara MA, Rodriguez M, Martin-Malo A, Aljama P: Monocytes from dialysis patients exhibit characteristics of senescent cells: does it really mean inflammation? in Ronco C, Brendolan A, Levin NW (eds): Cardiovascular Disorders in Hemodialysis. Contrib Nephrol. Basel, Karger, 2005, vol 149, pp 208-218. (Pubitemid 43265018)
15. Ramirez R, Carracedo J, Soriano S, Jimenez R, Martin-Malo A, Rodriguez M, Blasco M, Aljama P: Stress-induced premature senescence in mononuclear cells from patients on longterm hemodialysis. Am J Kidney Dis 2005; 45: 353-359. (Pubitemid 40431062)
16. Badger AM, Bernard DB, Idelson BA, Cooperband SR: Depressed spontaneous cellular cytotoxicity associated with normal or enhanced antibody-dependent cellular cytotoxicity in patients on chronic haemodialysis. Clin Exp Immunol 1981; 45: 568-575. (Pubitemid 11055952)
17. Lang I, Taraba I, Hering A, Petranyi G: Effect of haemodialysis on the antibody-dependent and spontaneous cell-mediated cytotoxicity of patients with chronic renal failure. Immunol Lett 1982; 5: 55-58. (Pubitemid 12052909)
18. Lang I, Taraba I, Petranyi G: Decreased antibody- dependent and spontaneous cell-mediated cytotoxicity in patients with chronic renal failure. Immunol Lett 1981; 3: 267-271. (Pubitemid 12206383)
19. Dechant M, Vidarsson G, Stockmeyer B, Repp R, Glennie MJ, Gramatzki M, van de Winkel JG, Valerius T: Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 2002; 100: 4574-4580. (Pubitemid 35429700)
20. Kelloff GJ, Sigman CC: Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov 2012; 11: 201-214.
21. Nimmerjahn F, Ravetch JV: Fcgamma receptors: old friends and new family members. Immunity 2006; 24: 19-28. (Pubitemid 43077197)
22. Veri MC, Gorlatov S, Li H, Burke S, Johnson S, Stavenhagen J, Stein KE, Bonvini E, Koenig S: Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIb (CD32b) from the activating Fcgamma- receptor IIa (CD32a): biochemical, biological and functional characterization. Immunology 2007; 121: 392-404. (Pubitemid 46817361)
23. Morel PA, Ernst LK, Metes D: Functional CD32 molecules on human NK cells. Leuk Lymphoma 1999; 35: 47-56. (Pubitemid 29454402)
24. Hernandez MR, Palomo M, Fuste B, Carbo C, Collado S, Cases A, Escolar G: Effect of two different dialysis membranes on leukocyte adhesion and aggregation. Nephron Clin Pract 2007; 106:c1-c8. (Pubitemid 46701507)
25. Zaoui P, Hakim RM: The effects of the dialysis membrane on cytokine release. J Am Soc Nephrol 1994; 4: 1711-1718.
26. Bloembergen WE, Hakim RM, Stannard DC, Held PJ, Wolfe RA, Agodoa LY, Port FK: Relationship of dialysis membrane and causespecific mortality. Am J Kidney Dis 1999; 33: 1-10. (Pubitemid 29031202)
27. Haufe CC, Eismann U, Deppisch RM, Stein G: Expression of beta2-microglobulin and cfos mRNA: is there an influence of high- or low-flux dialyzer membranes? Kidney Int Suppl 2001; 78:S177-S181. (Pubitemid 32144093)
28. Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacob HS: Complement and leukocyte- mediated pulmonary dysfunction in hemodialysis. N Engl J Med 1977; 296: 769-774. (Pubitemid 8064915)
29. Craddock PR, Hammerschmidt D, White JG, Dalmosso AP, Jacob HS: Complement (C5- a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia. J Clin Invest 1977; 60: 260-264. (Pubitemid 8145164)
30. Hernandez MR, Fuste B, Cases A, Tonda R, Escolar G, Ordinas A, Diaz-Ricart M: Haemodialysis through a cellulose membrane induces dephosphorylation of CD11b and promotes leukocyte adhesion to endothelial cells. Clin Invest Med 2009; 32:E48-E56.
31. Raj DS, Boivin MA, Dominic EA, Boyd A, Roy PK, Rihani T, Tzamaloukas AH, Shah VO, Moseley P: Haemodialysis induces mitochondrial dysfunction and apoptosis. Eur J Clin Invest 2007; 37: 971-977. (Pubitemid 350151187)
32. Lu J, Marjon KD, Mold C, Du Clos TW, Sun PD: Pentraxins and Fc receptors. Immunol Rev 2012; 250: 230-238.
33. Lech M, Rommele C, Anders HJ: Pentraxins in nephrology: C-reactive protein, serum amyloid P and pentraxin-3. Nephrol Dial Transplant 2013; 28: 803-811.
34. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P: Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-99. (Pubitemid 29313142)
35. Le Meur Y, Fixe P, Aldigier JC, Leroux-Robert C, Praloran V: Macrophage colony stimulating factor involvement in uremic patients. Kidney Int 1996; 50: 1007-1012. (Pubitemid 26302691)
36. Sester U, Sester M, Heine G, Kaul H, Girndt M, Kohler H: Strong depletion of CD14+ CD16+ monocytes during haemodialysis treatment. Nephrol Dial Transplant 2001; 16: 1402-1408. (Pubitemid 32640595)
37. Saionji K, Ohsaka A: Expansion of CD4+ CD16+ blood monocytes in patients with chronic renal failure undergoing dialysis: possible involvement of macrophage colonystimulating factor. Acta Haematol 2001; 105: 21-26. (Pubitemid 32424500)